406 related articles for article (PubMed ID: 34830196)
1. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 5: Epigenetic Regulation of PD-L1.
Palicelli A; Croci S; Bisagni A; Zanetti E; De Biase D; Melli B; Sanguedolce F; Ragazzi M; Zanelli M; Chaux A; Cañete-Portillo S; Bonasoni MP; Soriano A; Ascani S; Zizzo M; Castro Ruiz C; De Leo A; Giordano G; Landriscina M; Carrieri G; Cormio L; Berney DM; Gandhi J; Nicoli D; Farnetti E; Santandrea G; Bonacini M
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830196
[TBL] [Abstract][Full Text] [Related]
2. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models).
Palicelli A; Croci S; Bisagni A; Zanetti E; De Biase D; Melli B; Sanguedolce F; Ragazzi M; Zanelli M; Chaux A; Cañete-Portillo S; Bonasoni MP; Soriano A; Ascani S; Zizzo M; Castro Ruiz C; De Leo A; Giordano G; Landriscina M; Carrieri G; Cormio L; Berney DM; Gandhi J; Santandrea G; Bonacini M
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830179
[TBL] [Abstract][Full Text] [Related]
3. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer.
Sasidharan Nair V; El Salhat H; Taha RZ; John A; Ali BR; Elkord E
Clin Epigenetics; 2018; 10():78. PubMed ID: 29983831
[TBL] [Abstract][Full Text] [Related]
4. p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer.
Liu J; He D; Cheng L; Huang C; Zhang Y; Rao X; Kong Y; Li C; Zhang Z; Liu J; Jones K; Napier D; Lee EY; Wang C; Liu X
Oncogene; 2020 May; 39(19):3939-3951. PubMed ID: 32203167
[TBL] [Abstract][Full Text] [Related]
5. DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer.
Sasidharan Nair V; Toor SM; Taha RZ; Shaath H; Elkord E
Clin Epigenetics; 2018 Aug; 10(1):104. PubMed ID: 30081950
[TBL] [Abstract][Full Text] [Related]
6. Specific zinc finger-induced methylation of PD-L1 promoter inhibits its expression.
Li X; Wang Z; Huang J; Luo H; Zhu S; Yi H; Zheng L; Hu B; Yu L; Li L; Xie J; Zhu N
FEBS Open Bio; 2019 Jun; 9(6):1063-1070. PubMed ID: 31090214
[TBL] [Abstract][Full Text] [Related]
7. MLL3 enhances the transcription of PD-L1 and regulates anti-tumor immunity.
Xiong W; Deng H; Huang C; Zen C; Jian C; Ye K; Zhong Z; Zhao X; Zhu L
Biochim Biophys Acta Mol Basis Dis; 2019 Feb; 1865(2):454-463. PubMed ID: 30385408
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1.
Ramalho-Carvalho J; Martins JB; Cekaite L; Sveen A; Torres-Ferreira J; Graça I; Costa-Pinheiro P; Eilertsen IA; Antunes L; Oliveira J; Lothe RA; Henrique R; Jerónimo C
Cancer Lett; 2017 Jan; 385():150-159. PubMed ID: 27984115
[TBL] [Abstract][Full Text] [Related]
9. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
Wang H; Fu C; Du J; Wang H; He R; Yin X; Li H; Li X; Wang H; Li K; Zheng L; Liu Z; Qiu Y
J Exp Clin Cancer Res; 2020 Feb; 39(1):29. PubMed ID: 32024543
[TBL] [Abstract][Full Text] [Related]
10. miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways.
Majid S; Dar AA; Saini S; Shahryari V; Arora S; Zaman MS; Chang I; Yamamura S; Tanaka Y; Chiyomaru T; Deng G; Dahiya R
Clin Cancer Res; 2013 Jan; 19(1):73-84. PubMed ID: 23147995
[TBL] [Abstract][Full Text] [Related]
11. MiR-195/-16 Family Enhances Radiotherapy via T Cell Activation in the Tumor Microenvironment by Blocking the PD-L1 Immune Checkpoint.
Tao Z; Xu S; Ruan H; Wang T; Song W; Qian L; Chen K
Cell Physiol Biochem; 2018; 48(2):801-814. PubMed ID: 30032144
[TBL] [Abstract][Full Text] [Related]
12. The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion.
Lu C; Paschall AV; Shi H; Savage N; Waller JL; Sabbatini ME; Oberlies NH; Pearce C; Liu K
J Natl Cancer Inst; 2017 Jan; 109(6):. PubMed ID: 28131992
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic regulation of EFEMP1 in prostate cancer: biological relevance and clinical potential.
Almeida M; Costa VL; Costa NR; Ramalho-Carvalho J; Baptista T; Ribeiro FR; Paulo P; Teixeira MR; Oliveira J; Lothe RA; Lind GE; Henrique R; Jerónimo C
J Cell Mol Med; 2014 Nov; 18(11):2287-97. PubMed ID: 25211630
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic regulators of programmed death-ligand 1 expression in human cancers.
Kumar S; Sharawat SK
Transl Res; 2018 Dec; 202():129-145. PubMed ID: 30401465
[TBL] [Abstract][Full Text] [Related]
15. Identification of functional methylated CpG loci in PD-L1 promoter as the novel epigenetic biomarkers for primary gastric cancer.
Amini M; Hejazi M; Ghorban K; Mokhtarzadeh A; Baradaran B
Gene; 2021 Mar; 772():145376. PubMed ID: 33359128
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic silencing of miRNA-9 is correlated with promoter-proximal CpG island hypermethylation in gastric cancer in vitro and in vivo.
Li Y; Xu Z; Li B; Zhang Z; Luo H; Wang Y; Lu Z; Wu X
Int J Oncol; 2014 Dec; 45(6):2576-86. PubMed ID: 25270964
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic regulation of microRNA expression in colorectal cancer.
Bandres E; Agirre X; Bitarte N; Ramirez N; Zarate R; Roman-Gomez J; Prosper F; Garcia-Foncillas J
Int J Cancer; 2009 Dec; 125(11):2737-43. PubMed ID: 19521961
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic regulation of MDR1 gene through post-translational histone modifications in prostate cancer.
Henrique R; Oliveira AI; Costa VL; Baptista T; Martins AT; Morais A; Oliveira J; Jerónimo C
BMC Genomics; 2013 Dec; 14():898. PubMed ID: 24344919
[TBL] [Abstract][Full Text] [Related]
19. Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
Chen J; Jiang CC; Jin L; Zhang XD
Ann Oncol; 2016 Mar; 27(3):409-16. PubMed ID: 26681673
[TBL] [Abstract][Full Text] [Related]
20. KDM1A Promotes Immunosuppression in Hepatocellular Carcinoma by Regulating PD-L1 through Demethylating MEF2D.
Wang Y; Cao K
J Immunol Res; 2021; 2021():9965099. PubMed ID: 34307695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
